Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11110
Title: Nifedipine and experimental cardioprotection.
Austin Authors: Nayler, W G;Liu, J J;Panagiotopoulos, Sianna 
Affiliation: Department of Medicine, University of Melbourne, Austin Hospital, Victoria, Australia
Issue Date: 1-Aug-1990
Publication information: Cardiovascular Drugs and Therapy / Sponsored By the International Society of Cardiovascular Pharmacotherapy; 4 Suppl 5: 879-85
Abstract: Experimental studies using animal models designed to mimic the effect of ischemia and postischemic reperfusion have provided data indicating that the calcium antagonists might be cardioprotective. The laboratory studies have indicated consistently, however, that the timing of such drug administration is of critical importance. In the case of nifedipine (a dihydropyridine-based calcium antagonist), the laboratory studies have shown that when used prophylactically it has a protective effect during short (as in the "stunned heart") and long episodes (greater than 30 minutes) of ischemia. This protection has been quantitated in a variety of ways, including preservation of left ventricular function. A complete understanding of whether and how calcium antagonists can be used to protect the myocardium requires further detailed knowledge of not only of the voltage-activated calcium channel and its binding sites, but also of the sequence of events triggered by ischemia and reperfusion. Recent data from our laboratories indicate that cardiac membranes contain specific binding sites for the novel, endothelial-derived vasoconstrictor peptide, ET, and that the density of these sites increases during ischemia. ET promotes Ca2+ influx through the voltage-sensitive channels by a mechanism that does not involve a direct interaction with the dihydropyridine (DHP)-sensitive binding sites. Nevertheless, the ET-induced Ca2+ influx is attenuated by the dihydropyridine-based calcium channel blockers.
Gov't Doc #: 2076394
URI: https://ahro.austin.org.au/austinjspui/handle/1/11110
ORCID: 0000-0002-0845-0001
Journal: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy
URL: https://pubmed.ncbi.nlm.nih.gov/2076394
Type: Journal Article
Subjects: Animals
Aorta, Thoracic.drug effects.pathology
Arteriosclerosis.etiology.prevention & control
Binding Sites
Calcium.metabolism
Cholesterol.blood
Coronary Disease.drug therapy.metabolism
Endothelins.metabolism
Endothelium, Vascular.drug effects.ultrastructure
Female
Heart.drug effects
Myocardial Reperfusion Injury.drug therapy.metabolism
Myocardium.ultrastructure
Nifedipine.pharmacology
Rats
Rats, Inbred Strains
Time Factors
Triglycerides.blood
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.